Novartis: Purpura, Thrombocytopenic, Idiopathic trials
The registry lists 17 Purpura, Thrombocytopenic, Idiopathic studies with Novartis as lead sponsor. 6 are open to participants now and 6 have results posted.
Phase 2 7Phase 3 4Phase 4 1No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Patients' Preferences for Primary Immune Thrombocytopenia TreatmentRecruitingNCT07786077
- A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.Not yet recruitingNCT07660172Phase 2
- A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With EltrombopagRecruitingNCT07587723
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)RecruitingNCT07421167Phase 2
- Managed Access Programs for VAY736, IanalumabAvailableNCT07244289
- Managed Access Programs for ETB115, EltrombopagAvailableNCT04837703
- Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological DisordersTerminatedNCT05086744Phase 2Results posted
- A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITPCompletedNCT04346654Phase 2Results posted
- A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITPCompletedNCT03524612Phase 2Results posted
- A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)CompletedNCT02201290Phase 3Results posted
- A Rollover Study to Provide Continued Treatment With EltrombopagCompletedNCT01957176Phase 4Results posted
- EXTEND (Eltrombopag Extended Dosing Study)CompletedNCT00351468Phase 3Results posted
- A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia PatientsCompletedNCT07805408
- Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabWithdrawnNCT07039422Phase 2
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of TherapiesActive, not recruitingNCT05885555Phase 2
- Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)Active, not recruitingNCT05653349Phase 3
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed SteroidsActive, not recruitingNCT05653219Phase 3